AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18298356 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 65
Study 16212074 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD mode
Number of subjects: 23
Study 16212074 — intervention group
Group type: COMPARATOR
Intervention: VVI mode
Number of subjects: 23
Study 16212074 — intervention group
Group type: COMPARATOR
Intervention: VVIR mode
Number of subjects: 23
Study 12379063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin and pyrazinamide daily for 2 months (n = 307)
Number of subjects: 589
Study 12379063 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid daily for 6 months (n = 282)
Number of subjects: 589
Study 12379063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin and pyrazinamide
Number of subjects: 589
Study 12379063 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid
Number of subjects: 589
Study 10355952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting protocol
Number of subjects: 7
Study 10355952 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Number of subjects: 7
Study 10355952 — intervention group
Group type: COMPARATOR
Intervention: Supine protocol
Number of subjects: 7
Study 8576462 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Intensity Projection (MIP)
Number of subjects: 10
Study 8576462 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume Rendering
Number of subjects: 10
Study 8576462 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface Rendering
Number of subjects: 10
Study 1850142 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 200 mg
Number of subjects: 11
Study 1850142 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 600 mg
Number of subjects: 11
Study 1850142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6130073 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of buspirone
Number of subjects: 48
Study 6130073 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of diazepam
Number of subjects: 48
Study 6130073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6130073 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.85 g/kg for men; 0.72 g/kg for women)
Number of subjects: 48
Study 31420063 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback (automated feedback on a short monitoring questionnaire weekly)
Number of subjects: 0
Study 31420063 — intervention group
Group type: EXPERIMENTAL
Intervention: Featback with weekly e‐mail or chat support from an expert patient
Number of subjects: 0
Study 31420063 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly support from an expert patient
Number of subjects: 0
Study 31420063 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 0
Study 28651769 — intervention group
Group type: EXPERIMENTAL
Intervention: Space Closure Group (SCG)
Number of subjects: 16
Study 28651769 — intervention group
Group type: COMPARATOR
Intervention: Space Opening Group (SOG)
Number of subjects: 16
Study 26215525 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation using the VA HF COP
Number of subjects: 122
Study 26215525 — intervention group
Group type: COMPARATOR
Intervention: No facilitation (control)
Number of subjects: 122
Study 24573358 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal mesh
Number of subjects: 68
Study 24573358 — intervention group
Group type: COMPARATOR
Intervention: Vaginal colposuspension
Number of subjects: 68
Study 24573358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 23080350 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial injection of 30 mL of ropivacaine 0.5%
Number of subjects: 60
Study 23080350 — intervention group
Group type: COMPARATOR
Intervention: Extrafascial injection of 30 mL of ropivacaine 0.5%
Number of subjects: 60
Study 19374810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Number of subjects: 105
Study 19374810 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 16950429 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl‐L‐carnitine (6 g/day)
Number of subjects: 40
Study 16950429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15568141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.73 g/kg, 1 h before isoniazid, followed by 0.11 g/kg ethanol orally every hour thereafter for 7 h
Number of subjects: 16
Study 15568141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ethanol)
Number of subjects: 16
Study 11406779 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal cognitive score group (MMSE-K score >= 24)
Number of subjects: 449
Study 11406779 — intervention group
Group type: COMPARATOR
Intervention: Cognitive function test (MMSE-K)
Number of subjects: 449
Study 9209670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural combination of DDP (60 mg/m2) and CBDCA (270 mg/m2)
Number of subjects: 10
Study 9209670 — intervention group
Group type: COMPARATOR
Intervention: Single intravenous DDP treatment
Number of subjects: 10
Study 9209670 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of CBDCA alone
Number of subjects: 10
Study 7525697 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential type II mixed cryoglobulinemia
Number of subjects: 26
Study 7525697 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary type II mixed cryoglobulinemia
Number of subjects: 26
Study 3453426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 0
Study 3453426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31672681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh group (PMG) with onlay polypropylene mesh reinforcement
Number of subjects: 115
Study 31672681 — intervention group
Group type: COMPARATOR
Intervention: Suture group (SG) with slowly absorbable running sutures
Number of subjects: 115
Study 31672681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic mesh group (PMG)
Number of subjects: 115
Study 31672681 — intervention group
Group type: COMPARATOR
Intervention: Suture group (SG)
Number of subjects: 115
Study 30293364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with narrow-spectrum intense pulsed light and fractional carbon dioxide laser
Number of subjects: 90
Study 30293364 — intervention group
Group type: COMPARATOR
Intervention: Narrow-spectrum intense pulsed light alone (control group)
Number of subjects: 90
Study 30293364 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment group
Number of subjects: 90
Study 30293364 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 28634259 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPR (online Support Programme) offered via email over 6-7 months, including a Practical Support Booklet and educational videos.
Number of subjects: 569
Study 28634259 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (hearing aid fitting without SUPR) in 34 practices.
Number of subjects: 569
Study 26138472 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 811 (2 mg to 180 mg subcutaneously or 60 mg intravenously)
Number of subjects: 26
Study 26138472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 24169248 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 90
Study 24169248 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Number of subjects: 90
Study 24169248 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA I-gel
Number of subjects: 90
Study 21394052 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5‐mg ranibizumab
Number of subjects: 345
Study 21394052 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐mg triamcinolone
Number of subjects: 345
Study 21394052 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 345
Study 18329580 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-level laser therapy (LLLT) (Helium Neon, 632.8 nm, 30 mW)
Number of subjects: 52
Study 18329580 — intervention group
Group type: COMPARATOR
Intervention: Sham low-level laser therapy (placebo)
Number of subjects: 52
Study 14747424 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral dose of imatinib (capsule)
Number of subjects: 12
Study 14747424 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral dose of imatinib (oral solution)
Number of subjects: 12
Study 14747424 — intervention group
Group type: COMPARATOR
Intervention: 100 mg i.v. infusion of imatinib
Number of subjects: 12
Study 11113036 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg clonidine
Number of subjects: 10
Study 11113036 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine
Number of subjects: 10
Study 11113036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9738622 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Blood Order Equation (SBOE)
Number of subjects: 60
Study 9738622 — intervention group
Group type: COMPARATOR
Intervention: Maximal Surgical Blood Order Schedule (MSBOS)
Number of subjects: 60
Study 8283896 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm therapy based on on-site coagulation monitoring
Number of subjects: 66
Study 8283896 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 66
Study 2660970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization to house dust mite (D. pteronyssinus)
Number of subjects: 20
Study 2660970 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections for 1 year
Number of subjects: 20
Study 2660970 — intervention group
Group type: COMPARATOR
Intervention: Non-atopic asymptomatic controls
Number of subjects: 20
Study 5343357 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA (high oral dosage)
Number of subjects: 0
Study 31990328 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Me programme (intervention)
Number of subjects: 1120
Study 31990328 — intervention group
Group type: COMPARATOR
Intervention: Control (null group)
Number of subjects: 1120
Study 31325524 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural American Spirit (NAS) cigarettes
Number of subjects: 914
Study 31325524 — intervention group
Group type: COMPARATOR
Intervention: Pall Mall cigarettes
Number of subjects: 914
Study 31325524 — intervention group
Group type: EXPERIMENTAL
Intervention: Company behind NAS
Number of subjects: 914
Study 28987283 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 66
Study 28987283 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 66
Study 28987283 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 + 1 Hz rTMS
Number of subjects: 66
Study 26958115 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand A of Albendazole
Number of subjects: 715
Study 26958115 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand B of Albendazole
Number of subjects: 715
Study 26958115 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand C of Albendazole
Number of subjects: 715
Study 26958115 — intervention group
Group type: COMPARATOR
Intervention: All brands of Albendazole
Number of subjects: 715
Study 24051437 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAP (cell‐permeable peptide inhibitor)
Number of subjects: 0
Study 24051437 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (standard treatment)
Number of subjects: 0
Study 21536689 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted therapies
Number of subjects: 75
Study 21536689 — intervention group
Group type: COMPARATOR
Intervention: Weaker comparison conditions (e.g., wait-list controls)
Number of subjects: 75
Study 19192027 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 44
Study 19192027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16467234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention with intensive behavior modification to reduce total fat intake to 20% of calories and increase vegetables/fruits to 5 servings/d and grains to at least 6 servings/d.
Number of subjects: 48835
Study 16467234 — intervention group
Group type: COMPARATOR
Intervention: Comparison group received diet-related education materials.
Number of subjects: 48835
Study 16467234 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention.
Number of subjects: 48835
Study 15291859 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and high-dose epirubicin (360 mg, 12 instillations)
Number of subjects: 69
Study 15291859 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed and high-dose epirubicin (360 mg, 12 instillations)
Number of subjects: 69
Study 15291859 — intervention group
Group type: COMPARATOR
Intervention: Delayed low-dose epirubicin (180 mg, 30 mg once every 2 weeks, six times)
Number of subjects: 69
Study 15291859 — intervention group
Group type: COMPARATOR
Intervention: Early low-dose epirubicin (180 mg, three instillations before 7 days after TURBT)
Number of subjects: 69
Study 11256987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline, 0.5 mg three times daily for 2 weeks
Number of subjects: 24
Study 11256987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 400 microg twice daily for 2 weeks
Number of subjects: 24
Study 11256987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11256987 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 24
Study 11256987 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 24
Study 9048145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced methadone treatment
Number of subjects: 427
Study 9048145 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone treatment
Number of subjects: 427
Study 9048145 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder cocaine use
Number of subjects: 427
Study 9048145 — intervention group
Group type: EXPERIMENTAL
Intervention: Crack cocaine use
Number of subjects: 427
Study 9048145 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous users of powder cocaine
Number of subjects: 427
Study 9048145 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous speedball users
Number of subjects: 427
Study 9048145 — intervention group
Group type: EXPERIMENTAL
Intervention: Crack users
Number of subjects: 427
Study 8422139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat stitch
Number of subjects: 50
Study 8422139 — intervention group
Group type: COMPARATOR
Intervention: No fat stitch
Number of subjects: 50
Study 8422139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat stitch and No fat stitch
Number of subjects: 50
Study 8422139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 50
Study 2872914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular extraction and implantation of an iris supported lens (Federov I)
Number of subjects: 333
Study 2872914 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular extraction and implantation of an iridocapsular lens (Binkhorst 2‐loop)
Number of subjects: 333
Study 2872914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular extraction and contact lens usage
Number of subjects: 333
Study 31893302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold stimulation
Number of subjects: 15
Study 31893302 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour stimulation
Number of subjects: 15
Study 31893302 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonation stimulation
Number of subjects: 15
Study 31893302 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral stimulation
Number of subjects: 15
Study 29196825 — intervention group
Group type: EXPERIMENTAL
Intervention: FORTA-guided treatment
Number of subjects: 409
Study 29196825 — intervention group
Group type: COMPARATOR
Intervention: Standard geriatric treatment
Number of subjects: 409
Study 26889737 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV dengue vaccine
Number of subjects: 23
Study 24573730 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 120
Study 24573730 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 120
Study 22178602 — intervention group
Group type: EXPERIMENTAL
Intervention: New warning labels contradicting positive outcome expectancies
Number of subjects: 0
Study 20176771 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-minute training sessions, 3 days per week for 7 weeks at 65% of baseline oxygen uptake capacity
Number of subjects: 165
Study 20176771 — intervention group
Group type: COMPARATOR
Intervention: 60-minute training sessions, 3 days per week for 7 weeks at 65% of baseline oxygen uptake capacity
Number of subjects: 165
Study 20176771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both exercise volumes (40-minute and 60-minute)
Number of subjects: 165
Study 19132235 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management group (SMG)
Number of subjects: 195
Study 19132235 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (RCG)
Number of subjects: 195
Study 16190799 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 30
Study 16190799 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 30
Study 11929419 — intervention group
Group type: EXPERIMENTAL
Intervention: Decongestants (topical or oral)
Number of subjects: 0
Study 11929419 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 11929419 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamines
Number of subjects: 0
Study 11929419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal steroids
Number of subjects: 0
Study 11929419 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 11929419 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional methods
Number of subjects: 0
Study 11929419 — intervention group
Group type: EXPERIMENTAL
Intervention: Unknown medication
Number of subjects: 0
Study 11929419 — intervention group
Group type: COMPARATOR
Intervention: Rhinitis group
Number of subjects: 0
Study 11929419 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effectiveness
Number of subjects: 0
Study 9466525 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational vaccines (three types)
Number of subjects: 87
Study 7892924 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive services benefit added to Medicare
Number of subjects: 4195
Study 7892924 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive services benefit)
Number of subjects: 4195
Study 2705174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindmarsh operation
Number of subjects: 204
Study 2705174 — intervention group
Group type: COMPARATOR
Intervention: Bassini operation
Number of subjects: 204
Study 822964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (DSCG)
Number of subjects: 16
Study 822964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30907934 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 108
Study 30907934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 29025227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration anesthesia
Number of subjects: 25
Study 29025227 — intervention group
Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 25
Study 26602106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal culture device (IVC)
Number of subjects: 10
Study 26602106 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 10
Study 23153423 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary balloon angioplasty (PBA) of a long segment of the cephalic vein from the wrist up to the elbow (n=19)
Number of subjects: 40
Study 23153423 — intervention group
Group type: COMPARATOR
Intervention: Hydrostatic dilatation (HD) of a short venous segment (5 cm) at the level of the anastomosis (n=21)
Number of subjects: 40
Study 21299861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 24
Study 21299861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19564680 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct cellular communication
Number of subjects: 60
Study 19564680 — intervention group
Group type: COMPARATOR
Intervention: Indirect page communication
Number of subjects: 60
Study 17010462 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5mg/kg caffeine
Number of subjects: 20
Study 17010462 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0mg/kg caffeine
Number of subjects: 20
Study 17010462 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5mg/kg caffeine
Number of subjects: 20
Study 17010462 — intervention group
Group type: COMPARATOR
Intervention: 0mg/kg (placebo)
Number of subjects: 20
Study 12762972 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Number of subjects: 0
Study 12762972 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 12762972 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 12762972 — intervention group
Group type: EXPERIMENTAL
Intervention: Other interventions
Number of subjects: 0
Study 17224217 — intervention group
Group type: EXPERIMENTAL
Intervention: 60microg YIC immunization
Number of subjects: 20
Study 17224217 — intervention group
Group type: COMPARATOR
Intervention: Alum (control)
Number of subjects: 20
Study 10899491 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine HCl (2 microg/kg of body weight)
Number of subjects: 19
Study 10899491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8895283 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 micrograms/kg
Number of subjects: 80
Study 8895283 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.5 micrograms/kg
Number of subjects: 80
Study 8895283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 80
Study 1803847 — intervention group
Group type: EXPERIMENTAL
Intervention: Active buffering lozenge (Profylin)
Number of subjects: 33
Study 1803847 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge (not buffered)
Number of subjects: 33